CRISPR THERAPEUTICS Aktie

 

As time marches on, the factors that could make or break this stock are becoming crystal clear....

CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress....

CRISPR Therapeutics (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation. read more...

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $64.76, signifying a -1.97% move from its prior day's close....

Bereits zum Monatsanfang hat die Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics wieder an Fahrt aufgenommen. Am Freitag verzeichnet der AKTIONÄR-Depotwert erneut einen zweistelligen Kursanstieg. Während daher die Bullen jubeln, sind die Bären besonders enttäuscht....

George, Simeon - Aufsichtsrat - Tag der Transaktion: 2025-07-16...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $52.73, denoting a -6.54% move from the preceding trading day....

The average brokerage recommendation (ABR) for CRISPR Therapeutics (CRSP) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?...

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term....

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $51.19, representing a -1.88% change from its previous close....

Die Aktie des AKTIONÄR-Depotwerts CRISPR Therapeutics hat sich in den vergangenen Wochen enorm stark entwickelt. Zuletzt hat sich die Aufwärtsbewegung sogar noch einmal beschleunigt....

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects....

Based on the average brokerage recommendation (ABR), CRISPR Therapeutics (CRSP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?...

-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile-...

CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains....

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $46.78, marking a +2.7% move from the previous day....

CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field....

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $44.43, representing a +2.87% change from its previous close....

Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an annualized growth rate of approximately 63% over a decade.  This level of growth is extraordinary, transforming a modest sum into life-changing wealth that could potentially fund retirement, education, or entrepreneurial ventures. However, achieving this […] The post Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million? appeared first on 24/7 Wall St.....